Online Exclusives

BIO 2011 Wrapup

By Gil Roth | July 20, 2011

Video interviews from the world's biggest biotech show

The 2011 edition of the BIO International Convention marked a return to form for the world's biggest biotech event. Running from June 27-30 in Washington, DC, BIO attracted more than 15,000 attendees and 1,800 exhibitors. The event featured presentations and discussion with key policymakers and top scientists, covering a wide array of biotech topics.

Exhibitors told us that this year's event was stronger than in recent years, in terms of both floor-traffic and pre-arranged partnering meetings. Most credited this to an improving economy and a good host-city.

Biosimilars were a big topic of conversation, with many marketers discussing plans to enter that market. One bio-CMO remarked, "I'm glad that the U.S. is committed to developing a biosimilars pathway, but I have a feeling the group that'll see the biggest benefit is the lawyers."

Many were happy with the choice of venue, but expressed hope that BIO will generally rotate among key biotech regions — Boston, San Francisco, San Diego — for future conventions. The 2012 BIO International Convention will be held June 18-21 at the Boston Convention and Exhibition Center in Boston, Mass. For more information, visit http://convention.bio.org/2012.aspx.

Interviews:
  • Stephen C. Taylor, Ph.D., Commercial Director and Vice President, Fujifilm Diosynth Biotechnologies UK Ltd.
  • Peter Soelkner, Managing Director at Vetter Pharma International
  • Laura L. Parks, Ph.D., Senior Vice President Marketing & Sales, DSM Pharmaceuticals, Inc.
  • Shou Yi Poon, Manager, Business Servicies Division, International Enterprise Singapore
  • Michiel E. Ultee, Ph.D., Chief Scientific Officer, Laurate Biopharmaceutical Services
  • Kenneth Clapp, Senior Director, Global Marketing & Product Development, Xcellerex

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz||January 28, 2016

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.